Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,807 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.
Powis J, Peltekian KM, Lee SS, Sherman M, Bain VG, Cooper C, Krajden M, Deschenes M, Balshaw RF, Heathcote EJ, Yoshida EM; Canadian Pegasys Study Group. Powis J, et al. Among authors: lee ss. J Viral Hepat. 2008 Jan;15(1):52-7. doi: 10.1111/j.1365-2893.2007.00889.x. J Viral Hepat. 2008. PMID: 18088245 Free PMC article. Clinical Trial.
Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.
Bain VG, Lee SS, Peltekian K, Yoshida EM, Deschênes M, Sherman M, Bailey R, Witt-Sullivan H, Balshaw R, Krajden M; Canadian PEGASYS Study Group. Bain VG, et al. Among authors: lee ss. Aliment Pharmacol Ther. 2008 Jul;28(1):43-50. doi: 10.1111/j.1365-2036.2008.03705.x. Epub 2008 Apr 7. Aliment Pharmacol Ther. 2008. PMID: 18397386 Free article. Clinical Trial.
Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.
Yoshida EM, Sherman M, Bain VG, Cooper CL, Deschênes M, Marotta PJ, Lee SS, Krajden M, Witt-Sullivan H, Bailey RJ, Usaty C, Peltekian K; Pegasys Study Group. Yoshida EM, et al. Among authors: lee ss. Can J Gastroenterol. 2009 Mar;23(3):180-4. doi: 10.1155/2009/470532. Can J Gastroenterol. 2009. PMID: 19319382 Free PMC article.
Identifying HCV genotype 1 patients at risk of relapse.
Deschênes M, Bain VG, Lee SS, Sherman M, Cooper CL, Yoshida EM, Marotta PJ, Krajden M, Usaty C, Balshaw R, Peltekian KM; Canadian Pegasys Study Group. Deschênes M, et al. Among authors: lee ss. Eur J Gastroenterol Hepatol. 2010 May;22(5):546-51. doi: 10.1097/MEG.0b013e32832d237d. Eur J Gastroenterol Hepatol. 2010. PMID: 20216320
Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.
Lee SS, Sherman M, Ramji A, Greenbloom S, Elkashab M, Pluta H, Hilzenrat N, Balshaw R, Usaty C, Myers RP. Lee SS, et al. Aliment Pharmacol Ther. 2012 Jan;35(1):37-47. doi: 10.1111/j.1365-2036.2011.04911.x. Epub 2011 Nov 2. Aliment Pharmacol Ther. 2012. PMID: 22050141 Free article. Clinical Trial.
5,807 results